Combining TACE and HAIC for liver cancer treatment
Neoadjuvant Transartery Chemoembolization Plus Artery Infusion Chemotherapy With Surgery Versus Surgery Alone for Hepatocellular Carcinoma Patients With Barcelona Clinic Liver Cancer (BCLC) B Stage: a Randomized Clinical Trial
This study is testing if combining two types of chemotherapy for liver cancer can help patients live longer and keep their tumors from getting worse compared to just having surgery.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 280 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Sun Yat-sen University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT04424043 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of combining transarterial chemoembolization (TACE) with hepatic artery infusion chemotherapy (HAIC) in patients with BCLC B stage hepatocellular carcinoma (HCC) compared to surgery alone. The aim is to determine if this combination treatment can improve survival rates and reduce tumor progression in patients who are eligible for surgical resection. Participants will be randomly assigned to receive either the combination treatment or surgery alone, with a focus on evaluating tumor response and overall outcomes.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-75 with resectable BCLC B stage hepatocellular carcinoma and adequate liver function.
Not a fit: Patients with unresectable HCC or those who have received prior anti-HCC therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved survival rates for patients with BCLC B stage HCC.
How similar studies have performed: Previous studies have shown promising results with similar combination therapies, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * • Age 18-75 years; * BCLC B stage and tumor number \<=4; * Patients with resectable primary hepatocellular carcinoma; * Child-Pugh A or B (7 score) liver function; * The volume of residual liver more than 30% Exclusion Criteria: * • With unresectable HCC * Pregnant woman or sucking period; * With other malignant cancer; * Received anti-HCC therapy before this study
Where this trial is running
Guangzhou, Guangdong
- Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: Yunfei Yuan, MD. — Sun Yat-sen University
- Study coordinator: Jiliang Qiu, MD.
- Email: qiujl@sysucc.org.cn
- Phone: 862087343114
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.